SCHEMBL13726850

SCHEMBL13726850

COc1ccc(CNC(=O)c2nc(-c3ccccn3)nc(O)c2O)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.51
TAS1R1 Q7RTX1 2/20 0.51
ALDH1A1 P00352 3/20 0.48
TSHR P16473 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
GAA P10253 2/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 2/20 0.47
PKM P14618 1/20 0.47
TP53 P04637 6/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAOB P27338 1/20 0.47
ADORA2A P29274 1/20 0.47
MAPT P10636 2/20 0.46
THRB P10828 1/20 0.46
RXFP1 Q9HBX9 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128874 0.89 ADORA2A (0.55) ALDH1A1GAAHPGDHTTKMT2A
SCHEMBL13824294 0.85 EGLN1 (0.54) ALDH1A1HPGDKMT2AMEN1SMN1; SMN2
SCHEMBL5123516 0.84 ADORA2A (0.54) ALDH1A1TSHRGAAHPGDTP53
SCHEMBL5122964 0.83 MAOB (0.49) TAS1R3TAS1R1ALDH1A1TSHRNPSR1
SCHEMBL13729985 0.83 KMT2A (0.51) ALDH1A1TSHRNPSR1KMT2AMEN1
SCHEMBL5122030 0.81 MAPT (0.59) TAS1R3TAS1R1ALDH1A1TSHRNPSR1
SCHEMBL13727888 0.80 NPSR1 (0.54) NPSR1HPGDPKMTP53KMT2A
SCHEMBL13727825 0.79 ADORA2A (0.50) NPSR1TP53KMT2AMEN1ADORA2A
SCHEMBL5139688 0.78 MAOB (0.52) TAS1R3TAS1R1ALDH1A1TSHRNPSR1
SCHEMBL5128560 0.78 TP53 (0.59) TAS1R3TAS1R1ALDH1A1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328075-B2 Pyrimidinone compounds and methods for treating influenza ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-05-03 US disclosed
US-9328075-B2 Pyrimidinone compounds and methods for treating influenza ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-05-03 US disclosed
US-20140079666-A1 PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-03-20 US disclosed
US-20140079666-A1 PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-03-20 US disclosed
WO-2012151567-A1 PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2012-11-08 WO disclosed
WO-2012151567-A1 PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2012-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140079666-A1 PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA ADA, TYMP, ITPA TAS1R3 3741/4885TAS1R1 3448/4885ALDH1A1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.